1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2026.
−Removed: No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2026.
−Removed: Trading Arrangement
−Removed: Name and Position Action Date Rule
−Removed: 10b5-1* Non-Rule
−Removed: 10b5-1** Total Number of
−Removed: Shares to be Sold Expiration
−Removed: Brendan Teehan
−Removed: Chief Commercial Officer
−Removed: Adopt 3/5/2026 x 8,720 (1)
−Removed: Principal Accounting Officer
−Removed: Adopt 3/12/2026 x To Be Determined (2)
−Removed: * Intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: (1) The shares to be sold pursuant to the trading arrangement listed above are dependent on sale prices under the trading arrangement.
−Removed: (2) The aggregate number of shares to be sold pursuant to the trading arrangement listed above is dependent on, among other things, sale prices under the trading arrangement and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
+Added: During the quarter ended June 30, 2026, no director or executive officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
−Removed: Form of Performance Share Unit Agreement under the Amended and Restated 2011 Stock Incentive Plan.* ***
+Added: Stock and Asset Purchase Agreement by and between Pacira BioSciences, Inc., Pacira CryoTech, Inc.
+Added: and Zimmer, Inc.* #
+Added: Executive Employment Agreement, dated January 21, 2025, by and between Pacira Pharmaceuticals, Inc.
+Added: and Brendan Teehan.* †
+Added: Amended and Restated 2014 Employee Stock Purchase Plan.(1)†
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
3 unchanged sentences
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc.
−Removed: for the quarter ended March 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: for the quarter ended June 30, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) the Condensed Consolidated Balance Sheets;
(ii) the Condensed Consolidated Statements of Operations;
−Removed: (iii) the Condensed Consolidated Statements of Comprehensive Income;
+Added: (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss);
(iv) the Condensed Consolidated Statements of Stockholders’ Equity;
5 unchanged sentences
† Denotes management contract or compensatory plan or arrangement.
+Added: # Certain schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
+Added: The Registrant hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.
+Added: (1) Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on June 11, 2026.
Pacira BioSciences, Inc.
2 unchanged sentences
PACIRA BIOSCIENCES, INC.
−Removed: April 30, 2026 By:
+Added: August 4, 2026 By:
Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: April 30, 2026 By:
+Added: August 4, 2026 By:
Chief Financial Officer
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.